Beyond Weight Loss: How GLP-1 Receptor Agonists May Remodel the Tumor Microenvironment

Introduction

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of obesity and type 2 diabetes. Beyond their metabolic effects, emerging evidence suggests that GLP-1 signaling may influence tumor biology through modulation of immune function, inflammation, cellular metabolism, and stromal architecture. However, whether GLP-1RAs consistently promote an antitumor microenvironment remains uncertain, and emerging data suggest that their effects may differ substantially across tumor types. This review examines how GLP-1RAs may reshape the tumor microenvironment and explores the potential implications for tumor progression and therapeutic response.

Methods

A focused narrative review of contemporary literature was performed examining GLP-1 receptor signaling, GLP-1RA exposure, and the tumor microenvironment. Preclinical, translational, and available human studies were evaluated with emphasis on immune-cell composition and function, tumor-associated macrophages, T-cell and natural killer-cell activity, inflammatory signaling, extracellular matrix remodeling, and tumor metabolism. Evidence supporting both antitumor and potentially tumor-promoting effects was examined to characterize context-dependent responses across malignancies.

Results

Current evidence suggests that GLP-1RAs can influence multiple components of the tumor microenvironment. Preclinical studies demonstrate modulation of cytotoxic T-cell and natural killer-cell function, macrophage polarization, inflammatory signaling, and tumor metabolic pathways. In obesity-associated pancreatic cancer models, semaglutide reduced stromal and collagen deposition and increased intratumoral T-cell infiltration, suggesting remodeling of both physical and immune components of the tumor microenvironment. Experimental papillary thyroid carcinoma models similarly demonstrated macrophage reprogramming toward an increased M1 and decreased M2 phenotype with reduced tumor growth. Conversely, emerging evidence in triple-negative breast cancer has associated GLP-1 signaling with altered macrophage-tumor interactions, mesenchymal transition, and reduced response to chemoimmunotherapy. Collectively, available evidence suggests that GLP-1R signaling may reshape immune, stromal, and metabolic components of the tumor microenvironment, with effects that vary according to tumor context.

Conclusion

GLP-1RAs may represent previously underrecognized modulators of the tumor microenvironment rather than exclusively metabolic therapies. Current evidence suggests effects on immune-cell function, macrophage polarization, extracellular matrix composition, inflammatory signaling, and tumor metabolism; however, the direction and magnitude of these effects appear context-dependent. As GLP-1RA use continues to expand, prospective studies incorporating tumor tissue, spatial profiling, and immune phenotyping are needed to determine whether GLP-1RA exposure influences tumor progression or therapeutic response and to identify malignancies in which these effects may be clinically relevant.